Cyrus Biotechnology Scientist Erik Procko and the company’s lead ACE2-Fc Fusion protein COVID-19 therapeutic are featured in Science news article highlighting the exciting potential of decoy receptor drugs in fighting SARS-CoV-2, and other viral infections – (Science.com)
https://www.science.org/content/article/protein-decoys-viruses-may-battle-covid-19-and-more...
OpenFold AI Research Consortium Welcomes 4 New Members: Bayer, Dassault, CHARM Therapeutics and BaseCamp Research
OpenFold, a non-profit artificial intelligence (AI) research consortium whose goal is to develop free and open source software tools for biology and drug discovery, today announced the addition...
Cyrus Scientists Develop Tool for Peptide Design with Non-canonical Amino Acids
Technologies for discovering peptides as potential therapeutics have rapidly advanced in recent years with significant interest from both academic and pharmaceutical labs. These advancements in turn...
‘Decoy’ Protein Offers New Treatment Approach For Covid-19 – (Forbes.com)
This article is an excellent write up via William Haseltine of Forbes regarding the ACE2 research that scientists at Cyrus have been a part of...
Cyrus Biotechnology CEO Lucas Nivon featured in Fierce Biotech Webinar
Improving the discovery of novel drugs with artificial intelligence...
Cyrus ACE2.v2.4 candidate’s in vivo activity and prevention of lung damage demonstrated by University of Illinois College of Medicine department of Pharmacology – (Nature.com)
(Nature.com) – Vaccine hesitancy and emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) escaping vaccine-induced immune responses highlight the...
Cyrus Biotechnology’s COVID therapeutic lead, ACE2.v2.4, strongly binds and neutralizes SARS-CoV-2 omicron variant potentially providing long term protection
SEATTLE, WA – (BUSINESS WIRE) – Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary platform for biologics discovery that combines software, AI and large-scale...
Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm – (Businesswire)
SEATTLE, WA December 6, 2021 — Cyrus Biotechnology, Inc., a Seattle-based biotechnology firm with a proprietary software platform for biologics discovery, today announced the closing of a $18M...
Selecta Biosciences and Cyrus Biotechnology Enter Collaboration to Create Novel Engineered Therapeutic Proteins
– First collaboration program, leveraging Cyrus’ de novo computational approach to create proprietary IL-2 protein agonist targeting autoimmune and other deleterious immune conditions...
Scientific Summary: Cyrus NextGen Antibody structure prediction beats Schrodinger and others in a large independent benchmark
Over the last few years Cyrus has worked on problems on a range of proteins from enzymes to non-antibody biologics to vaccines to some antibody work. However most biologic drugs are monoclonal...
No post found
The future of AI in biologics drug discovery
The future of AI in biologics drug discovery By Sam DeLuca, Ph.D. With Steven Lewis, Ph.D. and Lucas Nivon, Ph.D. June 2023 In our previous article in March 2023, we discussed our experience...
The impact of new protein AI tools on real-world biologics discovery
Protein AI tools are useful for aggressive protein design, while physics based tools continue to be required for re-design of natural proteins for most cases By Steven Lewis, Dan Farrell, Brandon...
Foundation Models for Proteins: Cyrus, OpenFold and the future of biologics
Recent advances in the architecture and scale of AI are leading us from the era of narrowly focused AI (e.g. text auto-complete, immune epitope prediction in a protein sequence, antibody domain...
No post found
sign up for our newsletter now!
RECENT COMMENTS